Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · IEX Real-Time Price · USD
3.480
+0.240 (7.41%)
At close: Jul 19, 2024, 4:00 PM
3.420
-0.060 (-1.72%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Pyxis Oncology Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Pyxis Oncology stock have an average target of 9.83, with a low estimate of 7.00 and a high estimate of 15. The average target predicts an increase of 182.47% from the current stock price of 3.48.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 16, 2024.
Analyst Ratings
The average analyst rating for Pyxis Oncology stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +101.15% | May 16, 2024 |
| Jefferies | Jefferies | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +187.36% | May 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +101.15% | Apr 10, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $7 | Buy | Reiterates | $7 | +101.15% | Mar 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $4 → $7 | Strong Buy | Maintains | $4 → $7 | +101.15% | Mar 22, 2024 |
Financial Forecast
Revenue This Year
13.15M
Revenue Next Year
n/a
from 13.15M
EPS This Year
-1.08
from -1.85
EPS Next Year
-1.31
from -1.08
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 17.0M | n/a | 26.3M | 26.3M | 77.2M |
| Avg | 13.1M | n/a | 6.9M | 8.5M | 42.0M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 281.3% | 808.4% |
| Avg | - | - | - | 23.5% | 394.1% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.66 | -1.11 | -1.16 | -1.49 | -0.74 |
| Avg | -1.08 | -1.31 | -1.39 | -1.88 | -1.96 |
| Low | -1.40 | -1.46 | -1.71 | -2.04 | -2.65 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.